Thermal ablation versus radiotherapy for inoperable stage III non-small cell lung cancer: a propensity score matching analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Spencer KL, Kennedy MPT, Lummis KL, et al. Surgery or radiotherapy for stage I lung cancer? An intention-to-treat analysis. Eur Respir J. 2019;53(6):1801568.
   PubMed Web of Science ®Google Scholar
• Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ. 2021;375:n2363.
   PubMedGoogle Scholar
• Chaft JE, Rimner A, Weder W, et al. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021;18(9):547–557.
   PubMed Web of Science ®Google Scholar
• Daly ME. Inoperable early-stage non-small-cell lung cancer: stereotactic ablative radiotherapy and rationale for systemic therapy. J Clin Oncol. 2022;40(6):539–545.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Bauer TM, Ou SI, et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J Clin Oncol. 2022;40(31):3593–3602.
   PubMed Web of Science ®Google Scholar
• Cho BC, Abreu DR, Hussein M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781–792.
   PubMed Web of Science ®Google Scholar
• Uhlig J, Ludwig JM, Goldberg SB, et al. Survival rates after thermal ablation versus stereotactic radiation therapy for stage 1 non-small cell lung cancer: a national cancer database study. Radiology. 2018;289(3):862–870.
   PubMed Web of Science ®Google Scholar
• Ghosn M, Solomon SB. Current management of oligometastatic lung cancer and future perspectives: results of thermal ablation as a local ablative therapy. Cancers. 2021;13(20):5202.
   PubMed Web of Science ®Google Scholar
• Lin M, Eiken P, Blackmon S. Image guided thermal ablation in lung cancer treatment. J Thorac Dis. 2020;12(11):7039–7047.
   PubMed Web of Science ®Google Scholar
• Xu A, Zhang L, Yuan J, et al. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis. Cell Mol Immunol. 2019;16(10):820–832.
   PubMed Web of Science ®Google Scholar
• Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21.
   PubMed Web of Science ®Google Scholar
• Venturini M, Cariati M, Marra P, et al. CIRSE standards of practice on thermal ablation of primary and secondary lung tumours. Cardiovasc Intervent Radiol. 2020;43(5):667–683.
   PubMed Web of Science ®Google Scholar
• Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, et al. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506–518.
   PubMed Web of Science ®Google Scholar
• Park K, Vansteenkiste J, Lee KH, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Ann Oncol. 2020;31(2):191–201.
   PubMed Web of Science ®Google Scholar
• Daly ME, Singh N, Ismaila N, et al. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 2022;40(12):1356–1384.
   PubMed Web of Science ®Google Scholar
• Shang S, Wang R, Wang F, et al. Treatment patterns for patients with unresected stage III NSCLC: analysis of the surveillance, epidemiology, and end results (SEER) database. Front Oncol. 2022;12:874022.
   PubMed Web of Science ®Google Scholar
• Li M, Xu X, Qin Y, et al. Radiofrequency ablation vs. stereotactic body radiotherapy for stage IA non-small cell lung cancer in nonsurgical patients. J Cancer. 2021;12(10):3057–3066.
   PubMed Web of Science ®Google Scholar
• Aloysius MM, Goyal H, Shah NJ, et al. Impact of race and socioeconomics disparities on survival in young-onset colorectal adenocarcinoma-a SEER registry analysis. Cancers. 2021;13(13):3262.
   PubMed Web of Science ®Google Scholar
• Wao H, Mhaskar R, Kumar A, et al. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev. 2013;2(1):10.
   PubMedGoogle Scholar
• Yang WY, He Y, Hu Q, et al. Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: a propensity-matched analysis. Front Oncol. 2022;12:984932.
   PubMed Web of Science ®Google Scholar
• Yang H, Li M, Mei T. Survival benefit of thermal ablation combined with chemotherapy for the treatment of stage IV nonsmall cell lung cancer: a propensity-matched analysis. Int J Hyperthermia. 2022;39(1):348–357.
   PubMed Web of Science ®Google Scholar
• Liang L, Li G, Xie S, et al. Choice of treatment for stage IA non-small cell lung cancer patients ineligible for surgery: ablation or stereotactic body radiotherapy? J Cancer. 2020;11(6):1634–1640.
   PubMed Web of Science ®Google Scholar
• Zhang T, Bi N, Zhou Z, et al. The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy. J Thorac Dis. 2020;12(8):4347–4356.
   PubMed Web of Science ®Google Scholar
• Zeng C, Lu J, Tian Y, et al. Thermal ablation versus wedge resection for stage I non-small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database. Front Oncol. 2020;10:571684.
   PubMed Web of Science ®Google Scholar
• Ksienski D, Wai ES, Croteau NS, et al. Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab. J Geriatr Oncol. 2020;11(5):807–813.
   PubMed Web of Science ®Google Scholar
• Li LZ, Wu JM, Chen T, et al. Ablation therapy combined with EGFR TKIs in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2021;2021:6624429.
   PubMedGoogle Scholar
• Huang S, Li T, Chen Y, et al. Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6. Int J Hyperthermia. 2022;39(1):278–286.
   PubMed Web of Science ®Google Scholar
• Kim HK, Pyun JH, Cho S, et al. Tumor-specific immunity induced by cryoablation in a murine renal cell carcinoma model. Korean J Urol. 2014;55(12):834–840.
   PubMedGoogle Scholar
• Rangamuwa K, Leong T, Weeden C, et al. Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. Transl Lung Cancer Res. 2021;10(6):2842–2857.
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203.
   PubMed Web of Science ®Google Scholar